March 29 (Reuters) - Merck & Co Inc MRK.N:
POSITIVE DATA FROM PHASE 2 CADENCE TRIAL PROVIDES DEFINITIVE PROOF-OF-CONCEPT FOR WINREVAIR™ (SOTATERCEPT-CSRK) IN ADULTS WITH THE SYNDROME OF COMBINED POST- AND PRECAPILLARY PULMONARY HYPERTENSION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION
MERCK & CO INC - WINREVAIR MEETS PRIMARY ENDPOINT IN PHASE 2 CADENCE TRIAL
MERCK & CO: TOTALITY OF EVIDENCE ACROSS HEMODYNAMIC, FUNCTIONAL, ECHOCARDIOGRAPHIC AND CLINICAL ENDPOINTS SUPPORTS ADVANCING DEVELOPMENT OF WINREVAIR
MERCK & CO INC - WINREVAIR TO ADVANCE INTO REGISTRATIONAL PHASE 3 PROGRAM IN CPCPH-HFPEF